( rly those mentioned in the riskfactors...)An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes,Health

Prescribing information and patient product information for JANUVIA and JANUMET are attached.

JANUVIA(TM) and JANUMET(TM) are trademarks of Merck & Co., Inc. -0-

JANUVIA(TM)(sitagliptin) Tablets                     9762701


    HIGHLIGHTS OF PRESCRIBING INFORMATION


    These highlights do not include all the information needed to use

JANUVIA safely and effectively. See full prescribing information for

JANUVIA.


    JANUVIA(TM) (sitagliptin) Tablets


    Initial U.S. Approval: 2006


    INDICATIONS AND USAGE


    JANUVIA is indicated as an adjunct to diet and exercise to improve

glycemic control in patients with type 2 diabetes mellitus (type 2

diabetes). JANUVIA is indicated for:


    --  Monotherapy (1.1)


    --  Combination therapy with metformin or a peroxisome

        proliferator-activated receptor gamma (PPAR-gamma) agonist

        (e.g., thiazolidinediones) when the single agent does not

        provide adequate glycemic control. (1.2)


    Important Limitations of Use: JANUVIA should not be used in

patients with type 1 diabetes mellitus (type 1 diabetes) or for the

treatment of diabetic ketoacidosis. (1.3)


    DOSAGE AND ADMINISTRATION


    The recommended dose of JANUVIA is 100 mg once daily as

monotherapy or as combination therapy with metformin or a PPAR-gamma

agonist (e.g., thiazolidinediones). (2.1)


    JANUVIA can be taken with or without food. (2.1)



  Dosage Adjustment in Patients With Moderate, Severe and End Stage

                      Renal Disease (ESRD) (2.2)

----------------------------------------------------------------------

           50 mg once daily                   25 mg once daily

--------------------------------------------------------------------
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational
Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine
Extended Release, An Investigational Nonstimulant Medication Filed
for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole
in Adolescents With Schizophrenia